Phase 3 N=126 Role of Magnesium Supplementation in the Treatment of Depression
Depression
Primary: Patient Health Questionnaire-9 — -4.28; -0.09 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=656 A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant
Multiple Myeloma · Autologous Stem Cell Transplant
Primary: Progression Free Survival (PFS) — 21.3; 26.5 months — p=0.002
Phase 3 N=61 Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects
Post Operative Pain
Primary: Pain Intensity Score of Oxymorphone IR Oral Liquid in Pediatric Subjects by Age Group and Time Points in Single Dose Phase — 4.5; 3.4; 2.4; 3.5 score on a scale
Phase 3 N=61 Effects of Dalfampridine on Cognition in Multiple Sclerosis
Multiple Sclerosis
Primary: Symbol Digit Modalities Test — 41.18; 35.06; 45.05; 38.63 score on a scale
Phase 3 N=66 "Clinical Trial to Determine the Efficacy of Vitamin D for Acne Therapy"
Acne Vulgaris
Primary: Lesion Counts (Total, Inflammatory and Non-inflammatory) — 18.4; 13.4; 15.8; 9.9 Lesions
Phase 3 N=375 The Efficacy and Safety of PRC-063 in Adult ADHD Patients
ADHD
Primary: Change From Baseline in Clinician-administered ADHD-5-Rating Scale Total Score — 24.2; 19.9; 24.0; 18.7 units on a scale — p=0.6750
Phase 3 N=1,820 Long-term Safety and Efficacy of Sirukumab in Participants With RA Completing Studies CNTO136ARA3002 or CNTO136ARA3003
Arthritis, Rheumatoid
Primary: Percentage of Participants With Serious Adverse Events (SAEs) — 21.3; 27.8; 26.4; 23.1 Percentage of participants
Phase 3 N=1,845 A Safety and Efficacy Study of the Combination Estradiol and Progesterone to Treat Vasomotor Symptoms
Menopause
Primary: Co-Primary Efficacy Endpoint: Frequency of Moderate to Severe Vasomotor Symptoms (MITT-VMS) — -40.6; -35.1; -33.6; -38.9 weekly hot flushes — p=<0.001
Phase 3 N=76 A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Participants 5 to 18 Years of Age With Neurogenic Detrusor Overactivity
Neurogenic Detrusor Overactivity
Primary: Change From Baseline to Week 24 in Maximum Cystometric Capacity (MCC) — 57.2; 59.3 mL — p=<0.001
Phase 3 N=746 Capsaicin + Diclofenac Gel in Acute Back Pain or Neck Pain
Acute Pain
Primary: Change in POM Between Baseline and Day 2 Evening, 1 Hour After Drug Application — -2.45; -3.26; -2.33; -3.05 Units on a scale — p=0.0303
Phase 3 N=179 Efficacy and Safety Evaluating Study to Compare Kanarb (Fimasartan) and Cozaar® (Losartan) in Adult Patients With Grade I-II Arterial Hypertension
Arterial Hypertension
Primary: Change in Systolic Blood Pressure (SBP) After 12 Weeks of Treatment — 152.9; 151.9; -25.2; -24.3 mm Hg — p==0.390
Phase 3 N=39,679 Zambia Chlorhexidine Application Trial
Sepsis
Primary: All-cause Neonatal Mortality — 282; 263; 18168; 19045 participants
Phase 3 N=397 A Study to Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Asthma
Asthma
Primary: Clinical Asthma Exacerbation (CAE) Rate: Percentage of Participants Who Experienced at Least 1 Moderate or Severe CAE — 17 percentage of participants
Phase 3 N=132 A Study With SAGE-547 for Super-Refractory Status Epilepticus
Super-Refractory Status Epilepticus
Primary: Number of Participants Able to be Weaned Off All Third-Line Agents Prior to End of Double-Blind SAGE-547 or Placebo Infusion, and Remain Off All Third-Line Agents for ≥…
Phase 3 N=112 Phase III Study of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer
Malignant Neoplasm of Breast
Primary: Progression Free Survival (PFS) — 42; 46; 14; 10 Participants